Difference between revisions of "Umbralisib (Ukoniq)"

Code name: TGR-1202
Brand name: Ukoniq

Revision as of 13:42, 6 February 2021

Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor

2/5/2021: Approved for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
2/5/2021: Approved for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

Revision as of 13:42, 6 February 2021 (view source) Jwarner (talk \| contribs) m ← Older edit	Revision as of 13:42, 6 February 2021 (view source) Jwarner (talk \| contribs) m (Jwarner moved page Umbralisib (TGR-1202) to Umbralisib (Ukoniq): FDA approval with new brand name) Newer edit →
(No difference)